OS Therapies (OSTX) News Today $1.95 -0.65 (-25.00%) Closing price 04:00 PM EasternExtended Trading$2.00 +0.05 (+2.56%) As of 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period OS Therapies (NYSE:OSTX) Earns "Buy" Rating from D. Boral CapitalD. Boral Capital reaffirmed a "buy" rating and set a $20.00 price objective on shares of OS Therapies in a research report on Thursday.January 30 at 9:35 AM | marketbeat.comOS Therapies Inc's Lock-Up Period Will Expire on January 28th (NYSE:OSTX)OS Therapies' (NYSE:OSTX - Get Free Report) lock-up period is set to end on Tuesday, January 28th. OS Therapies had issued 1,600,000 shares in its IPO on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. After the expiration of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.January 21, 2025 | marketbeat.comOS Therapies Inc (NYSE:OSTX) Major Shareholder Sells $112,692.80 in StockJanuary 18, 2025 | insidertrades.comos therapies sees $112,609 in stock sales by Einodmil LLCJanuary 17, 2025 | msn.comShalom Auerbach Sells 16,720 Shares of OS Therapies Inc (NYSE:OSTX) StockOS Therapies Inc (NYSE:OSTX - Get Free Report) major shareholder Shalom Auerbach sold 16,720 shares of the business's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $6.74, for a total value of $112,692.80. Following the completion of the transaction, the insider now owns 2,531,211 shares of the company's stock, valued at $17,060,362.14. This represents a 0.66 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.January 17, 2025 | marketbeat.comOS Therapies price target raised to $15 from $8 at MaximJanuary 17, 2025 | finance.yahoo.comOS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patientsJanuary 16, 2025 | msn.comOS Therapies: A Cheap Mid-Stage Biotech Carrying Listeria-Based ImmunotherapyJanuary 16, 2025 | seekingalpha.comOS Therapies (NYSE:OSTX) Price Target Raised to $15.00 at Maxim GroupMaxim Group lifted their price objective on shares of OS Therapies from $8.00 to $15.00 and gave the company a "buy" rating in a report on Thursday.January 16, 2025 | marketbeat.comOS Therapies' (OSTX) Buy Rating Reiterated at D. Boral CapitalD. Boral Capital restated a "buy" rating and set a $20.00 price target on shares of OS Therapies in a research note on Wednesday.January 16, 2025 | marketbeat.comOS Therapies up 65% as lung osteosarcoma asset meets goal in phase 2 trialJanuary 15, 2025 | msn.comD. Boral Capital Reiterates "Buy" Rating for OS Therapies (NYSE:OSTX)D. Boral Capital reaffirmed a "buy" rating and issued a $20.00 price target on shares of OS Therapies in a report on Wednesday.January 15, 2025 | marketbeat.comOS Therapies stock soars on Phase 2b trial successJanuary 15, 2025 | in.investing.comOS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic OsteosarcomaJanuary 15, 2025 | businesswire.comRockville's OS Therapies raises millions to get cancer treatment to marketJanuary 8, 2025 | bizjournals.comOS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | finance.yahoo.comOS Therapies Announces Closing of $6 Million Private PlacementDecember 31, 2024 | businesswire.comOS Therapies Partners with B2i Digital to Engage with Biotech Investors OnlineDecember 26, 2024 | businesswire.comOS Therapies to sell 1.5M units at $4.00 in private placementDecember 25, 2024 | finance.yahoo.comOS Therapies Prices Private Placement Of 1.5 Mln Units At $4/Unit, Stock RisesDecember 24, 2024 | markets.businessinsider.comOS Therapies Announces Pricing of $6 Million Private PlacementDecember 24, 2024 | businesswire.comOS Therapies (NYSE:OSTX) Shares Up 35.3% - Time to Buy?OS Therapies (NYSE:OSTX) Trading 35.3% Higher - Here's WhyDecember 18, 2024 | marketbeat.comMaxim Group Initiates Coverage of OS Therapies (OSTX) with Buy RecommendationNovember 27, 2024 | msn.comOS Therapies Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 15, 2024 | businesswire.comOSTX Stock Earnings: OS Therapies Reported Results for Q2 2024November 15, 2024 | investorplace.comOSTX Stock Earnings: OS Therapies Reported Results for Q2 2024November 12, 2024 | investorplace.comOSTX Stock Earnings: OS Therapies Reported Results for Q2 2024November 11, 2024 | investorplace.comOS Therapies to Present at The Spartan Capital Investor ConferenceNovember 5, 2024 | finance.yahoo.comJoin OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30October 30, 2024 | tmcnet.comOS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of DirectorsOctober 28, 2024 | businesswire.comOS Therapies to Present at the LD Micro Main Event XVIIOctober 24, 2024 | uk.finance.yahoo.comOS Therapies (NYSE:OSTX) Stock Price Down 0.9% - Time to Sell?OS Therapies (NYSE:OSTX) Shares Down 0.9% - Here's What HappenedOctober 22, 2024 | marketbeat.comOS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual SummitOctober 17, 2024 | finance.yahoo.comOS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient VisitOctober 3, 2024 | finance.yahoo.comOS Therapies (NYSE:OSTX) Trading Up 0.3%OS Therapies (NYSE:OSTX) Trading 0.3% HigherSeptember 27, 2024 | marketbeat.comOS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic CandidatesSeptember 13, 2024 | finance.yahoo.comOS Therapies Incorporated (OSTX)September 12, 2024 | finance.yahoo.comOS Therapies reports positive preclinical data for ovarian cancer treatmentSeptember 11, 2024 | proactiveinvestors.comOS Therapies Inc OSTXSeptember 7, 2024 | morningstar.comOS Therapies Inc (OSTX)September 6, 2024 | uk.investing.comOS Therapies (NYSE:OSTX) Stock Rating Upgraded by EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I upgraded shares of OS Therapies to a "strong-buy" rating in a research report on Tuesday.September 5, 2024 | marketbeat.comOS Therapies Inc's (NYSE:OSTX) Quiet Period Will End on September 10thOS Therapies' (NYSE:OSTX - Get Free Report) quiet period is set to expire on Tuesday, September 10th. OS Therapies had issued 1,600,000 shares in its IPO on August 1st. The total size of the offering was $6,400,000 based on an initial share price of $4.00. During OS Therapies' quiet period, insiders and any underwriters involved in the IPO are restricted from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the expiration of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.September 3, 2024 | marketbeat.com Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address OSTX Media Mentions By Week OSTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OSTX News Sentiment▼0.000.75▲Average Medical News Sentiment OSTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OSTX Articles This Week▼22▲OSTX Articles Average Week Get OS Therapies News Delivered to You Automatically Sign up to receive the latest news and ratings for OSTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Molecular Partners News Today Ocugen News Today Candel Therapeutics News Today Gossamer Bio News Today Compugen News Today Aurora Cannabis News Today Acelyrin News Today MacroGenics News Today Monopar Therapeutics News Today Organigram News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:OSTX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OS Therapies Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share OS Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OSTX Stock Alerts